Analysis Research

 
Stock Quotes for Analysis Research top ^
  • Industry: Software - Application
  • Sector: Technology
  • Stock Type: Slow Growth
Sign-up for iaic investment picks
  • Industry: Software - Application
  • Sector: Technology
  • Stock Style: Large Core
  • Stock Type: Slow Growth
Sign-up for iaic investment picks

 
Fund Quotes for Analysis Research top ^
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsmx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsfx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsix investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsrx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 1 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for FLSLX investment picks

 
News Articles for Analysis Research top ^
2013/10/22
NEW YORK and REDWOOD CITY, California and HILDEN, Germany , October 22, 2013 /PRNewswire/ -- Mount Sinai collaboration with QIAGEN Center of Excellence in Biological Interpretation demonstrates translational value of high-quality analysis of gene variants in rare diseases Accuracy and ease of use for clinical and labora to ry geneticists and other medical professionals are cited in selection of genomic analysis solutions from QIAGEN Medical school also will use Ingenuity Variant Analysis   to   train next generation of medical professionals in genome interpretation QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai in New York City have adopted the Ingenuity ® Variant Analysis™ solution for research and
Sign-up for QIAGEN's Ingenuity® Variant Analysis™ Selected for Translational Genomics by Icahn School of Medicine at Mount Sinai investment picks
NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the availability of the nCounter ® Dx Analysis System for high-complexity, CLIA-certified laboratories.
Sign-up for NanoString Launches the nCounter Dx Analysis System for U.S. Market investment picks
2014/1/27
CA Technologies (NASDAQ:CA) today announced a new version of CA Network Flow Analysis that leverages Cisco’s next-generation technology to provide IT organizations with application-centric insights to better spot anomalies, improve service levels and reduce operational costs.
Sign-up for CA Network Flow Analysis Leverages Cisco’s Next-Generation Technology to Deliver Deep Insight into Application Performance investment picks
NanoString Technologies and BD Biosciences Sign Collaboration Agreement to Develop Single Cell Isolation and Analysis Workflow SEATTLE and SAN JOSE, Calif.
Sign-up for New Workflow to Provide Scientists with Tools That Enable Single Cell Analysis for Oncology, Immunology and Stem Cell Research investment picks
2013/11/25
Company will Resubmit the Contrave NDA in the Next Few Weeks - Potential Approval by June 2014 SAN DIEGO , Nov.
Sign-up for Orexigen Announces Successful Interim Analysis of Contrave Light Study investment picks
LightTools version 8.1 is now generally available MOUNTAIN VIEW, Calif.
Sign-up for Latest Release of Synopsys' LightTools Delivers Faster Performance and Superior Illumination Analysis Features investment picks
Affymetrix, Inc. (NASDAQ:AFFX) announces the launch of Axiom Strawberry Genotyping Array (also called International Strawberry 90K SNP array or IStraw90), the only solution that successfully enables high-resolution genotyping and fully automated data analysis of the octoploid strawberry genome.
Sign-up for Affymetrix Axiom® Strawberry Genotyping Array Delivers Automated Analysis for High-Resolution Genome Scanning of Octoploid Strawberry investment picks
-- Demonstrated clinically meaningful activity regardless of baseline platelet counts -- -- No clinically significant treatment-emergent anemia or thrombocytopenia with 36 percent of patients remaining on therapy for 18 months or longer -- --
Sign-up for Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting investment picks
2013/12/13
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies.
Sign-up for PAM50-Based Prosigna Breast Cancer Assay Helps to Identify Patients at Risk of Late Distant Recurrence in a Combined Analysis of 2,137 Patients investment picks
Rand Worldwide (OTCBB: RWWI) , a global leader in providing technology solutions to organizations with engineering design and information technology requirements, today announces the expansion of IMAGINiT Technologies ’ Computational Fluid Dynamics (CFD) Analysis Consulting group .
Sign-up for IMAGINiT Technologies CFD Consulting Group Expands as Businesses Realize Benefits of Simulation and Analysis Consulting investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Analysis Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Analysis Report  |  Next: Analysis Shows